The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer

Author(s): Kanika Gupta, Jacob Elkon, Ehab El-Bahesh, Jeanny B. Aragon-Ching

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 16 , Issue 9 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Prostate cancer is the most common cancer among American men and the second most common cause of cancer deaths among men. Treatment of prostate cancer remains a challenge. Despite decades of research, few cytotoxic chemotherapy agents have shown promise against prostate cancer. In this paper, we will discuss the history of chemotherapy in prostate cancer, the pivotal trials with docetaxel that advanced the field, the cytotoxic chemotherapy agents, including cabazitaxel, as well as combination therapy with docetaxel or cabazitaxel and the potential implications of biomarkers such as AR-V7 in chemotherapy use.

Keywords: Chemotherapy, prostate cancer, docetaxel, cabazitaxel.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 15 August, 2016
Page: [1166 - 1171]
Pages: 6
DOI: 10.2174/1871520616666160121113558
Price: $65

Article Metrics

PDF: 67